Fighting malaria
Research insight to Nobel laureate Tu
malaria was traditionally treated by chloroquine or quinine, but with declining success. By the late 1960s, efforts to eradicate Malaria had failed and the disease was on the rise. At that time, Youyou Tu in China turned to traditional herbal medicine to tackle the challenge of developing novel Malaria therapies. From a large-scale screen of herbal remedies in Malaria-infected animals, an extract from the plant Artemisia annua emerged as an interesting candidate.

Youyou Tu searched ancient literature on herbal medicine in her quest to develop novel malaria therapies. The plant Artemisia annua turned out to be an interesting candidate, and Tu developed a purification procedure, which rendered the active agent, Artemisinin, a drug that is remarkably effective against Malaria.
Nobel Foundation
However, the results were inconsistent, so Tu revisited the ancient literature and discovered clues that guided her in her quest to successfully extract the active component from Artemisia annua. Tu was the first to show that this component, later called Artemisinin, was highly effective against the Malaria parasite, both in infected animals and in humans. Artemisinin represents a new class of antimalarial agents that rapidly kill the Malaria parasites at an early stage of their development, which explains its unprecedented potency in the treatment of severe Malaria.
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Artificial intelligence could improve therapy for lymphoma
Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
Yale Researchers Discover New Potential Asthma Therapeutic Targets Related to Parasites and Insects
Protagen Expands Cooperation with Bayer HealthCare
Emergent BioSolutions Announces Appointment of Ronald Richard to the Board of Directors

Deadly combination: new direct trigger for cell death discovered - Understanding the basic mechanisms that lead to cell death is essential for the development of therapies for cancer and other diseases

Bayer: Supervisory Board extends CEO Werner Baumann’s - Contract until the end of April 2024

Restoring vision by gene therapy - Latest scientific findings give hope for people with incurable retinal degeneration
Pantec Biosolutions receives ISO 13485 certification
Stora Enso awarded as Finland’s most startup-friendly company
Genetic screening before embryo transfer fails to improve the chance of a baby
